Head-to-head · Cost-Efficiency Index
Aquivia Health vs AZ Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Aquivia Health
Cost-first shoppers who want clinician-reviewed compounded GLP-1 with optional branded upgrade.
Visit Aquivia HealthAZ Health
Cost-first shoppers who want transparent flat-rate compounded GLP-1 pricing in the roughly half of states it covers, if you confirm eligibility first.
Visit AZ HealthThe verdict
Aquivia Health takes it, leading the Cost-Efficiency Index 62 to 61. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound. AZ Health still earns a C — Cost-first shoppers who want transparent flat-rate compounded GLP-1 pricing in the roughly half of states it covers, if you confirm eligibility first.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Aquivia Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Aquivia Health | AZ Health |
|---|---|---|
| Cost-Efficiency Index | 62/100 | 61/100 |
| Semaglutide / mo | $149/mo | $179/mo (starting dose, compounded) |
| Tirzepatide / mo | $179/mo | $199/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $1,788 | $2,148 |
| Tirzepatide / yr (modeled) | $2,148 | $2,388 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #217 | #223 |
Aquivia Health
62/100Where the value is
- Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
- Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
- Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
The tradeoffs
- No public list of states served — you must complete intake to learn if your state qualifies
- No named 503A compounding pharmacy partner, limiting licensure verification
AZ Health
61/100Where the value is
- Transparent flat monthly pricing published up front — semaglutide from $179/mo, tirzepatide from $199/mo, no insurance required
- Discloses plainly that compounded medications are not FDA-approved
- FSA/HSA eligible, free discreet shipping, and cancel-anytime language
The tradeoffs
- Coverage is stated only as '50% States Covered' with no state list published — you cannot confirm eligibility before starting
- The.org domain and thin site (an /faq link 404s) are unusual for a commercial telehealth business and warrant extra caution
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.